Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - cyclopentolate hydrochloride, quantity: 10 mg/ml - eye drops, solution - excipient ingredients: potassium chloride; purified water; hydrochloric acid; benzalkonium chloride; boric acid; disodium edetate; sodium carbonate monohydrate - indications as at 27 june 1996: for mydriasis nad cycloplegia in diagnostic procedures. for some pre- and post-operative states when mydriasis is required and when a shorter acting mydriatic and cycloplegic is needed in the therapy of iridocyclitis.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 200 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; maize starch; lactose monohydrate - antiepileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs.,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties, clinical trials).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; sodium starch glycollate; maize starch; lactose monohydrate; microcrystalline cellulose - antiepileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs.,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties, clinical trials).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 50 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; lactose monohydrate; maize starch; magnesium stearate - antiepileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs.,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties, clinical trials).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - lamotrigine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate; lactose monohydrate; magnesium stearate; microcrystalline cellulose; maize starch - antiepileptic drug for the treatment of partial and generalised seizures in adults and children over 12 years of age.,there is extensive experience with lamotrigine used initially as add-on therapy. the use of lamotrigine has also been found to be effective as monotherapy following withdrawal of concomitant antiepileptic drugs.,initial monotherapy treatment in newly diagnosed paediatric patients is not recommended (see section 5.1 pharmacodynamic properties, clinical trials).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - cipla ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - cipla ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - ambrisentan, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; titanium dioxide; purified talc; allura red ac aluminium lake; polyvinyl alcohol; macrogol 3350; lecithin - ambrisentan is indicated for the treatment of: - idiopathic pulmonary arterial hypertension (pah), - pulmonary artrial hypertension associated with connective tissue disease (pah-ctd),,in patients with who functional class ii, iii or iv symptoms.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and adolescents over 16 years of age.